Heat shock protein 90 inhibitors in non-small-cell lung cancer

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 159-164

  Pillai, Rathi N ^a   Ramalingam, Suresh S ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Anaplastic lymphoma kinase; Epidermal growth factor receptor; Ganetespib; Heat shock protein 90 inhibitors; Non small cell lung cancer

Indexed keywords

BENZAMIDES; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOINDOLES; ISOXAZOLES; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RESORCINOLS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84894047818     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000047     Document Type: Review

References (22)

1. Mahalingam D, Swords R, Carew JS, et al. Targeting HSP90 for cancer therapy. Br J Cancer 2009; 100:1523-1529
2. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: Moving into the clinic. Lancet Oncol 2013; 14: E358-e369
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30
4. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined nonsmall-cell lung cancer. J Clin Oncol 2010; 28:4953-4960
5. Normant E, Paez G, West KA, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011; 30:2581-2586
6. Riely GJ, Gettinger SN, Stoller RG, et al. Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (Suppl):abstr7516
7. Ying W, Du Z, Sun L, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012; 11:475-484
8. Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA-9090), a nongeldanamycinHSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small-cell lung cancer. Clin Cancer Res 2012; 18:4973-4985
9. Proia DA, Sang J, He S, et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small-cell lung cancer models. Invest New Drugs 2012; 30:2201-2209
10. Acquaviva J, Smith DL, Sang J, et al. Targeting KRAS-mutant non-small-cell lung cancer with the Hsp90 inhibitor ganetespib. Mol Cancer Ther 2012; 11:2633-2643
11. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small-cell lung cancer. Clin Cancer Res 2013; 19:3068-3077
12. Kauh JS, Harvey RD, Owonikoko TK, et al. A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies. J Clin Oncol 2012; 30 (Suppl):abstr3094
13. Ramalingam SS, Goss GD, Andric ZG, et al. A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). J Clin Oncol 2013; 31 (Suppl):CRA8007
14. Ramalingam SS, Shapiro G, Hirsh V, et al. GALAXY-1: Randomized phase II study of docetaxel with or without ganetespib in advanced lung adenocarcinoma-results in biomarker sub-groups and all adenocarcinoma patients. J Thorac Oncol 2013; 8 (Suppl 2):S139
15. Sessa C, Shapiro GI, Bhalla KN, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res 2013; 19:3671-3680
16. Johnson ML, Hart EM, Rademaker A, et al. A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). J Clin Oncol 2013; 31 (Suppl):abstr 8036
17. Yu HA, Johnson ML, Urman A, et al. A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) in patients with EGFR-mutant lung cancer and acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013; 8 (Suppl 2):S596
18. Nogova L, Bos M, Gardizi M, et al. A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. J Thorac Oncol 2013; 8 (Suppl 2):S914-S915
19. Graham B, Curry J, Smyth T, et al. The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-smallcell lung cancer. Cancer Sci 2012; 103:522-527
20. Hearn K, Smyth T, Lewis J, et al. The Hsp90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and-resistant models of EGFRactivated NSCLC. J Thorac Oncol 2013; 8 (Suppl 2):S464
21. Smyth T, Munck J, Rodriguez-Lopez A, et al. Combining the Hsp90 inhibitor, AT13387, with crizotinib improves response in an ALK positive model of NSCLC. J Thorac Oncol 2013; 8 (Suppl 2):S163
22. Mahadevan DR, Rensvold DM, Kurtin SE, et al. First-in-human phase I study: Results of a second-generation nonansamycin heat shock protein 90 (HSP90) inhibitor AT13387 in refractory solid tumors. J Clin Oncol 2012; 30 (Suppl):abstr3028